Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

mpharm stage 3 > musculoskeletal system > Flashcards

musculoskeletal system Flashcards

1
Q

What is osteopenia

A

Reduction in bone mineral content

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is osteoporosis

A

Reduction in bone mass

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the main causes of osteoporosis

A

1) post menopausal oestrogen deficiency

2) Age related bone haemostasis deterioration

3)long term levothyroxine use

4) long term glucocorticoid therapy

5) Myeloma (bone marrow cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is osteomalacia

A

softening of bones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pharmalogical treatment osteoporosis

A

1)Bisphosphonates
- given if BMD is -2.5 or lower e.g. alendronate, risedronate, zoledronic acid).

  • usually paired with calcium and vitamin D (colecafierol).

2) SERMs: e.g. Raloxifene to increase osteoblast activity and reduce osteoclast activity
- low bioavailability but is well distributed

3) Strontium ranelate: Reduces osteoclast activity and increases osteoblast activity.

4) PTH (teriparatide, abaloparatide) : increase bone mass by stimulating increase in number of osteoblasts, and decreasing osteoblast apoptosis.
- They act on PTh-1 receptors and activate adenylyl cyclase, to increase Ca2= levels.

5) monoclonal antibodies (Denosumab): Binds to RANKL to inhibit osteoclast formation.

6) Romosozumab: inhibits sclerostin, causing increase in bone matrix production by osteoclasts.

7) Hormone replacement therapy (HRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Non Pharmalogical management to treat osteoporosis

A

1) Excercise

2) Smoking cessation

3) reducing alcohol intake

4) more calcium (at least 700mg a day) and viatamin D

5) weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

non Pharmalogical management for OA

A

mobility aids
Exercise
weight management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pharmalogical management for OA

A

1) Topical nsaids

2) oral nsaids
combo with gastro protective to (e.g. PPI:
omeprazole).

3) intra articular corticosteroid injection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

pharmalogical mangement for RA

A

DMARDs (methotrexate, sulfasalazine).
NSAIDs to control symptoms

also if DMARDs given then, short term bridging treatment with glucocorticoids is also given.

DMARDs can take 2-3 months to be effective.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is a cDMARD

A

conventional DMARD
just normal DMARDs like methortrexate etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

examples of biologicla DMARDs used to treat RA

A

Adalimumab
etanercept
infliximab
certolizumab pegol
golimumab

tocilizumab
abatacept

1) top 5 inhibit activity of tumor necrosis factor alpha, and a pro-inflammatory mediator responsible for damge to joints.

2) Adacept binds to APCs, preventing activation of t lymphocytes, disrupting inflmmatory process.

3) Tocilizumab inhibits interleukin-6 (pro-inflammaootry mediator resposible for joint pain in RA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the suffix for a monoclinal antiboy

A

mab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

methotrexate mechanism of action

A

1) Inhibits dihydrofolate reductase
preventing formation of tetrahydrofolate
reducing proliferatiion of immune cells

2) Increases release of adenosine, reduced immune cell activation at joints

3) Suppresses t lymphocyte activation, reducing production of cytokines, reducing synovial inflamation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

examples of JAK inhibitors to treat RA

A

Tofacitinib x2 a day

Baricitinib

upadacitinib

filgotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

draw backs for pharmalogiccal treatment for RA

A

increased risk of ifection, due to constant supression or decrease in immune response with DMARDs etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is JIA

A

juvenile idiopathic arthiritis

its RA in kids

DMARD: methotreate
sulfasalzine is avoided in sytemic onset JIA

17
Q

non Pharmalogical management for RA

A

exercise: muscle strengthening and joint flexibility
physiotherapy
footwear support

18
Q

What blood test is done for gout

A

serum urate levels

19
Q

pharmalogical mangement for gout

A

NSAID, colchicine, oral corticosteroid

if nsaids given then PPI also given as a gastro-protective agent.

if gout is severe then allopurinol (anti gout agent) given instead.

20
Q

mechanism of action of colchicine

A

disrupts cytoskeletal function by inhibiting B-tubulin polymerisation into microtubules.

anti gout agent general moa: Reduce uric acid production by inhibiting the activity of xanthine oxidase

21
Q

allopurinol drug class and mechanism of action

A

xanthine oxidase inhibitor

inhibits xanthine oxidase preventing conversion of hypoxanthine into xanthine into uric acid.

22
Q

non pharmalogical treatment of gout

A
  • reduce alch intake
  • weight loss
  • diet (e.g. Mediterranean).
23
Q

levothyroxine

A

Drug Class: Thyroid hormone replacement
Indication: Hypothyroidism (underactive thyroid)
Mechanism of Action: Levothyroxine is a synthetic form of thyroxine (T4) that is converted to triiodothyronine (T3) in the body. It increases metabolic activity, growth, and development by replacing the deficient thyroid hormones in hypothyroid patients.
Side Effects:
Common: Palpitations, anxiety, weight loss, heat intolerance, tremors.
Severe: Arrhythmias, chest pain, hyperthyroidism (if dose is too high).

24
Q

Alendoronate

A

Drug Class: Bisphosphonate
Indication: Osteoporosis, Paget’s disease of bone
Mechanism of Action: Alendronate inhibits osteoclast-mediated bone resorption, increasing bone mineral density by preventing bone loss and reducing fracture risk.
Side Effects:
Common: Abdominal pain, nausea, heartburn.
Severe: Esophageal ulcers, osteonecrosis of the jaw, atypical femoral fractures

25
raloxifene
Drug Class: Selective estrogen receptor modulator (SERM) Indication: Osteoporosis, breast cancer prevention in postmenopausal women Mechanism of Action: Raloxifene acts as an estrogen agonist on bone, reducing resorption and increasing BMD. Side Effects: Common: Hot flashes, leg cramp, Swelling in the hands or feet, Joint pain Headache Severe: Deep vein thrombosis (DVT), pulmonary embolism (PE).
26
strontium ranelate
Drug Class: Bone-forming agent Indication: Osteoporosis (in postmenopausal women and men) Mechanism of Action: Strontium ranelate increases bone formation and reduces bone resorption, improving bone strength and reducing fracture risk. Side Effects: Common: Nausea, diarrhea. Severe: Cardiovascular events (e.g., heart attack, stroke), venous thromboembolism.
27
teriparatide
Drug Class: Parathyroid hormone analog Indication: Osteoporosis (in high-risk patients) Mechanism of Action: Teriparatide is a recombinant form of parathyroid hormone (PTH) that stimulates bone formation by activating osteoblasts, enhancing bone density and strength. Side Effects: Common: Nausea, dizziness, leg cramps. Severe: Osteosarcoma (rare), hypercalcemia.
28
denosumab
Drug Class: Monoclonal antibody Indication: Osteoporosis, bone metastases, bone loss due to cancer treatment Mechanism of Action: Denosumab inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), a protein that promotes osteoclast differentiation and activation, thereby reducing bone resorption. Side Effects: Common: Back pain, muscle pain, hypocalcemia. Severe: Osteonecrosis of the jaw, atypical femoral fractures.
29
romosozumab
Drug Class: Monoclonal antibody Indication: Osteoporosis (in postmenopausal women at high fracture risk) Mechanism of Action: Romosozumab inhibits sclerostin, preventing bone formation from being inhbited, thereby stimulating both bone formation and reducing bone resorption. Side Effects: Common: Joint pain, headache, back pain. Severe: Cardiovascular events (e.g., heart attack, stroke)
30
omeprazole
Drug Class: Proton pump inhibitor (PPI) Indication: GERD, peptic ulcers, Zollinger-Ellison syndrome Mechanism of Action: Omeprazole inhibits the proton pump (H+/K+ ATPase) in parietal cells of the stomach, reducing gastric acid production. Side Effects: Common: Headache, abdominal pain, nausea. Severe: Bone fractures, Clostridium difficile infection, kidney disease.
31
methotrexate side effects
Drug Class: Antimetabolite, Disease-modifying anti-rheumatic drug (DMARD) Indication: Rheumatoid arthritis, psoriasis, certain cancers Side Effects: Gastrointestinal issues (nausea, vomiting, stomach pain) Mouth ulcers (oral mucositis) Fatigue or feeling tired Hair thinning (usually mild) Mild liver enzyme elevations advise: folic acid supplements
32
sulfasalazine
Drug Class: Disease-modifying anti-rheumatic drug (DMARD), anti-inflammatory Indication: Rheumatoid arthritis, inflammatory bowel disease (e.g., ulcerative colitis) Mechanism of Action: Sulfasalazine is metabolized into sulfapyridine and 5-aminosalicylic acid. It reduces inflammation by inhibiting cyclooxygenase and lipoxygenase pathways. Side Effects: Common: Nausea, rash, headache, loss of appetite, abdominal discomfort. Severe: Blood dyscrasias, liver toxicity, hypersensitivity reactions. advice: take with food to reduce GI irritation
33
adalimumab
Drug Class: Monoclonal antibody, TNF-alpha inhibitor Indication: Rheumatoid arthritis, Crohn's disease, psoriasis, ankylosing spondylitis Mechanism of Action: Adalimumab binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, reducing inflammation. Side Effects: Common: Injection site reactions, headache. Severe: Increased risk of infections (e.g., tuberculosis), malignancies, hepatotoxicity.
34
abatacept
Drug Class: Monoclonal antibody, T-cell co-stimulation modulator Indication: Rheumatoid arthritis, juvenile idiopathic arthritis Mechanism of Action: Abatacept inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells, preventing their interaction with CD28 on T-cells. Side Effects: Common: Headache, nasopharyngitis. Severe: Increased risk of infections, malignancies, infusion reactions.
35
tofacitinib
Drug Class: Janus kinase (JAK) inhibitor Indication: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis Mechanism of Action: Tofacitinib inhibits Janus kinase enzymes (JAK1, JAK2, JAK3), which are involved in signaling pathways for immune cell activation, reducing inflammation. Side Effects: Common: Headache, upper respiratory infections. Severe: Risk of infections, blood clots, lymphoma, liver enzyme elevations.
36
colchicine
Drug Class: Anti gout agent Indication: Gout, familial Mediterranean fever Mechanism of Action: Colchicine inhibits microtubule polymerization, reducing neutrophil migration and inflammation in affected joints. Side Effects: Common: Diarrhea, nausea, vomiting. Severe: Bone marrow suppression, rhabdomyolysis, liver toxicity.
37
allopurinol
Drug Class: Xanthine oxidase inhibitor Indication: Gout, hyperuricemia, prevention of uric acid stones Mechanism of Action: Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting purines into uric acid, thus lowering uric acid levels. Side Effects: Common: Rash, gastrointestinal upset. Severe: Stevens-Johnson syndrome, liver toxicity, kidney failure.
38
tocilizumab
Drug Class: Monoclonal antibody, IL-6 receptor antagonist Indication: Rheumatoid arthritis, cytokine release syndrome, systemic juvenile idiopathic arthritis Mechanism of Action: Tocilizumab inhibits IL-6 receptors, reducing the inflammatory response mediated by IL-6. Side Effects: Common: Upper respiratory infections, headache. Severe: Liver enzyme elevation, gastrointestinal perforations, serious infections.

mpharm stage 3 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions